107 unchanged sentences
Form of Investor Warrant, dated September 12, 2014.
−Removed: Form of Common Stock Purchase Warrant, dated May 10, 2017.
Form of Representative’s Warrant, dated August 3, 2017.
16 unchanged sentences
Form of Investor Warrant issued January 27, 2021.
+Added: Form of Placement Agent Warrant issued January 27, 2021.
Description of Document
−Removed: of placement agent warrant issued January 27, 2021.
−Removed: of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc.
+Added: Form of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc.
and the purchasers signatory thereto.
−Removed: of investor warrant issued February 19, 2021.
+Added: Form of Investor Warrant issued February 19, 2021.
Form of Placement Agent Warrant issued February 19, 2021
+Added: Description of Common Stock
Citius Pharmaceuticals, Inc.
2 unchanged sentences
2014 Stock Incentive Plan Nonqualified Stock Option.
−Removed: Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., executed March 30, 2016, effective March 1, 2016.
+Added: Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., executed April 12, 2022, effective May 1, 2022.
Second Amendment to the Patent and Technology License Agreement between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc., dated March 20, 2017.
1 unchanged sentence
Amended and Restated Demand Convertible Promissory Note between Leonard Mazur and Citius Pharmaceuticals, Inc., dated May 10, 2017.
−Removed: Warrant Agent Agreement between VStock Transfer, LLC and Citius Pharmaceuticals, Inc., dated August 3, 2017.
Amended and Restated Employment Agreement between Leonard Mazur and Citius Pharmaceuticals, Inc., dated October 19, 2017.
9 unchanged sentences
First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc.
−Removed: Description of Document
Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc.
+Added: Description of Document
Form of Securities Purchase Agreement, dated April 1, 2019, by and between Citius Pharmaceuticals, Inc.
29 unchanged sentences
Reddy’s Laboratories S.A.
−Removed: Description of Document
Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd.
4 unchanged sentences
Subsidiaries.
+Added: Description of Document
Consent of Independent Registered Public Accounting Firm.
1 unchanged sentence
Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).
−Removed: Certification of the Chief
−Removed: Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
−Removed: 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley
−Removed: Inline XBRL Instance Document
−Removed: Inline XBRL Taxonomy Extension Schema Document.
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Presentation Linkbase
−Removed: Cover Page Interactive Data File (formatted as Inline
−Removed: XBRL and contained in Exhibit 101).
−Removed: of this exhibit have been omitted pursuant to Item 601(b)10 of Regulation S-K.
+Added: Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
+Added: 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
+Added: XBRL INSTANCE DOCUMENT
+Added: XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
+Added: XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
+Added: XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
+Added: XBRL TAXONOMY EXTENSION LABELS LINKBASE
+Added: XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
+Added: + Portions of this exhibit have been omitted pursuant to Item
+Added: 601(b)10 of Regulation S-K.
Form 10-K Summary.
5 unchanged sentences
December 22, 2022
−Removed: /s/ Myron Holubiak
−Removed: Myron Holubiak
−Removed: President and Chief Executive Officer
+Added: /s/ Leonard Mazur
+Added: Leonard Mazur
+Added: Chief Executive Officer
(Principal Executive Officer)
3 unchanged sentences
/s/ Leonard Mazur
−Removed: Executive Chairman of the Board of Directors
+Added: Chief Executive Officer and Director
December 22, 2022
Leonard Mazur
+Added: (Principal Executive Officer)
/s/ Myron Holubiak
−Removed: President and Chief Executive Officer and Director
+Added: Executive Vice Chairman and Director
December 22, 2022
Myron Holubiak
−Removed: (Principal Executive Officer)
−Removed: /s/ Jaime Bartushak
−Removed: Chief Financial Officer and Chief Accounting Officer
+Added: /s/ Jaimie Bartushak
+Added: Chief Financial Officer
December 22, 2022
13 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.